Orphan Drugs Market Partnering Deals and Agreements by Healthcare Companies Reviewed in New Research Report at RnRMarketResearch.com
Dallas, TX (PRWEB) August 10, 2013 -- The Orphan Drugs Partnering Terms and Agreements report provide an understanding and access to the orphan drugs partnering deals and agreements entered into by the world’s leading healthcare companies.
Trends in orphan drugs partnering deals.
Disclosed headlines, Upfronts, milestones and royalties by stage of development.
Orphan drugs partnering contract documents.
Top orphan drug deals by value.
The Orphan Drugs Partnering Terms and Agreements report provide an understanding and access to the orphan drugs partnering deals and agreements entered into by the world’s leading healthcare companies.
Get a copy of this report at http://www.rnrmarketresearch.com/orphan-drugs-partnering-terms-and-agreements-market-report.html.
The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drug technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 140 links to online copies of actual orphan drugs deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of orphan drugs dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in orphan drugs dealmaking since 2007, including details of disclosed headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading orphan drugs deals since 2007. Deals are listed by headline value, signed by big pharma and big biotech, and most active of all Biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of orphan drugs deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of orphan drugs deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 and 7 provides a comprehensive and detailed review of orphan drugs partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in orphan drugs partnering and dealmaking since 2007.
In addition, a comprehensive appendix is provided organized by orphan drugs partnering company A-Z, deal type definitions and orphan drugs partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan drugs technologies and products.
Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=72737.
Browse more reports on Diseases & treatment Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment.
About Us:
RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Priyank Tiwari, RnRMarketResearch.com, http://www.rnrmarketresearch.com/, +1-888-391-5441, [email protected]
Share this article